Brief History

The Division of Hematology and Oncology has a long history of providing compassionate, personal service to those suffering from cancer and blood disorders. The Division is a leader in early drug development, human cancer genetics, and biological response modifiers in the treatment of cancer and its complications. Molecular biology, pharmacology, biochemistry and basic immunology are integral parts of the Division's developmental therapeutics and cancer immunology programs. The Division of Hematology and Oncology has 30 faculty, who see over 1,000 outpatients/month at clinic facilities within the James Cancer Center, Kenny Road, and Stoneridge. In addition, the faculty care for over 2,560 inpatients at the James. James Cancer Hospital and Richard J. Solve Research Institute (James), an NCCN designated free standing comprehensive cancer center, where patients with the primary diagnosis of cancer are seen and treated. The James houses 160 inpatient beds and services 40 cancer specific clinics and is continuing to expand to accommodate additional faculty, patients, and research missions.

Goals and Objectives

Trainees will qualify for examination by the American Board of Internal Medicine in medical oncology or hematology/oncology after successful completion of the two or three-year program, respectively. The program’s primary objective is to train clinically competent, compassionate, board eligible physicians with a broad knowledge of medical oncology and hematology through a combination of intensive inpatient service exposure on Oncology, Hematology, Leukemia, Stem cell transplant, and Consult service; rotations including Gynecology/Oncology, Radiation Oncology, Neuro-Oncology, Hematopathology, Blood banking, and Hospice and Palliative Care, and broad outpatient exposure through continuity, ambulatory, and elective clinic blocks. In addition, fellows are required to dedicate a portion of their fellowship to either laboratory-based research or clinical research which provides training in laboratory assays in cancer medicine, conducting and reporting clinical trials, and communication with other physician scientists. Finally, the program offers a wealth of didactic and patient-oriented educational experiences through weekly formal case review conferences, journal club, tumor boards, board review, basic lecture series, and teaching attending rounds.

Training of Programs

The fellowship program in the Division of Hematology and Oncology at The Ohio State University offers two distinct training tracts: (1) a 3-year hematology/oncology training program which offers trainees dual board eligibility in hematology and oncology in accordance with the American Board of Internal Medicine standards, and (2) a 2-year medical oncology training program which offers trainees board eligibility in medical oncology in accordance with the American Board of Internal Medicine standards. Both tracts offer intensive clinical training (18 months for dual certification and 12 months for oncology certification) and protected research time. Fellows are encouraged to spend research time participating in clinical, laboratory, or translation research. Individuals with the M.D., M.D./Ph.D, or D.O. degrees are invited to apply and are accepted into the program on the basis of merit and an interest in pursuing careers as physician-scientists or basic scientists focused on translational cancer research.